American Bio Medica (OTCMKTS:ABMC – Get Free Report) and ImmuCell (NASDAQ:ICCC – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
Profitability
This table compares American Bio Medica and ImmuCell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| American Bio Medica | N/A | N/A | N/A |
| ImmuCell | -1.82% | -1.88% | -1.22% |
Valuation & Earnings
This table compares American Bio Medica and ImmuCell”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| American Bio Medica | N/A | N/A | N/A | ($0.02) | N/A |
| ImmuCell | $27.64 million | 3.19 | -$1.04 million | ($0.06) | -162.33 |
American Bio Medica has higher earnings, but lower revenue than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than American Bio Medica, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
13.5% of ImmuCell shares are held by institutional investors. 3.1% of American Bio Medica shares are held by insiders. Comparatively, 5.7% of ImmuCell shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for American Bio Medica and ImmuCell, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| American Bio Medica | 0 | 0 | 0 | 0 | 0.00 |
| ImmuCell | 1 | 0 | 0 | 0 | 1.00 |
Given American Bio Medica’s higher possible upside, research analysts clearly believe American Bio Medica is more favorable than ImmuCell.
Summary
American Bio Medica beats ImmuCell on 5 of the 9 factors compared between the two stocks.
About American Bio Medica
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers a test for the detection of respiratory syncytial virus; OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to unaffiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, North America, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
About ImmuCell
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Receive News & Ratings for American Bio Medica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Bio Medica and related companies with MarketBeat.com's FREE daily email newsletter.
